1 / 33

West Midlands Regional Training Package for Safe Blood Transfusion Practice

Module 3: Clinical Indications for Use. Contents:Principle: Minimise the Need for Donor Blood Products.Guidelines for the Use of Red Cell Transfusions.Guidelines for the Use of Platelet Transfusions.Guidelines for the Use of Fresh Frozen Plasma.Guidelines for the Use of Cryoprecipitate.Special Requirements

ivo
Download Presentation

West Midlands Regional Training Package for Safe Blood Transfusion Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. West Midlands Regional Training Package for Safe Blood Transfusion Practice

    2. Module 3: Clinical Indications for Use Contents: Principle: Minimise the Need for Donor Blood Products. Guidelines for the Use of Red Cell Transfusions. Guidelines for the Use of Platelet Transfusions. Guidelines for the Use of Fresh Frozen Plasma. Guidelines for the Use of Cryoprecipitate. Special Requirements – CMV, irradiated and HLA-matched.

    3. Principle: Minimise the need for donor blood products

    4. Principle: Minimise the need for donor blood products

    5. National Guidelines

    7. National Guidelines

    8. Guidelines for the use of red cell transfusions

    9. Guidelines for the use of red cell transfusions

    10. An algorithm for the use of red cells. Reproduced with acknowledgement to Dept of Haematology, The Alexandra Hospital, Redditch.

    11. Transfusion in Chronic Anaemia

    12. Transfusion Dependant Anaemia

    13. Transfusion Dependant Anaemia

    14. Guidelines for the use of platelets

    15. Guidelines for the use of platelets

    16. Module 3: Clinical Indications for Use

    17. Guidelines for the use of Plasma Components

    18. FFP may be indicated

    19. FFP is NOT indicated

    20. Guidelines for the use of Cryoprecipitate

    21. ‘Special Requirements’

    22. What is Cytomegalovirus (CMV)?

    23. Indication for the use of CMV-seronegative Blood Components

    24. What is Transfusion-Associated Graft-versus-Host Disease (TA-GvHD)?

    25. Indications for the Use of Irradiated Blood Components

    26. What are HLA-matched platelets?

    27. Key Points

    28. Module 3 - Quiz Question 1 of 6 The decision to transfuse should be decided on: A. The patient’s FBC results B. Patient’s symptoms, signs and laboratory findings C. The patient’s pallor D. An agreed haemoglobin target

    29. Module 3 - Quiz Question 2 of 6 Patients with chronic anaemia are deficient in red cells and have a decreased blood volume. True / False

    30. Module 3 - Quiz Question 3 of 6 Platelet transfusions are indicated in patients who have: A. Heparin induced thrombocytopaenia. B. Thrombocytopaenia due to Bone Marrow failure. C. Treatment of haemorrhage in all patients. D. All patients who have a platelet count < 50.

    31. Module 3 - Quiz Question 4 of 6 FFP may be indicated in which of the following conditions: A. Reversal of heparin anticoagulation associated with significant bleeding if prothrobin complex concentrate is not available. B. Renal disease to support treatment of bleeding or prior to surgery. C. Massive transfusion if the coagulation tests are significantly prolonged (PT >1.5 x normal). D. Routine correction of abnormal coagulation screen.

    32. Module 3 - Quiz Question 5 of 6 CMV may cause a serious infection in: A. Immunocompetent patients. B. Immunocompromised patients. C. All patients found to be CMV –ve. D. Any patient receiving a CMV +ve blood product.

    33. Module 3 - Quiz Question 6 of 6 All patients at risk of developing TA-GvHD should have blood components irradiated prior to transfusion. True / False

    34. Module 3 – Quiz Answers Question1: B Question 2: False Question 3: B Question 4: C Question 5: B Question 6: True

More Related